DK200801600A - Method for treatment of inflammatory diseases - Google Patents
Method for treatment of inflammatory diseases Download PDFInfo
- Publication number
- DK200801600A DK200801600A DKPA200801600A DKPA200801600A DK200801600A DK 200801600 A DK200801600 A DK 200801600A DK PA200801600 A DKPA200801600 A DK PA200801600A DK PA200801600 A DKPA200801600 A DK PA200801600A DK 200801600 A DK200801600 A DK 200801600A
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- mentioned
- dermatitis
- diabetes
- induce
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 14
- 238000000034 method Methods 0.000 title claims 10
- 238000011282 treatment Methods 0.000 title claims 6
- 150000001875 compounds Chemical class 0.000 claims 15
- 201000004624 Dermatitis Diseases 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000013566 allergen Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 208000001280 Prediabetic State Diseases 0.000 claims 3
- 208000010247 contact dermatitis Diseases 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 claims 3
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 claims 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 claims 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 claims 2
- KZTWOUOZKZQDMN-UHFFFAOYSA-N 2,5-diaminotoluene sulfate Chemical compound OS(O)(=O)=O.CC1=CC(N)=CC=C1N KZTWOUOZKZQDMN-UHFFFAOYSA-N 0.000 claims 2
- OBCSAIDCZQSFQH-UHFFFAOYSA-N 2-methyl-1,4-phenylenediamine Chemical compound CC1=CC(N)=CC=C1N OBCSAIDCZQSFQH-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010033898 parapsoriasis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229940005561 1,4-benzoquinone Drugs 0.000 claims 1
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 claims 1
- 229940075142 2,5-diaminotoluene Drugs 0.000 claims 1
- MGLZGLAFFOMWPB-UHFFFAOYSA-N 2-chloro-1,4-phenylenediamine Chemical compound NC1=CC=C(N)C(Cl)=C1 MGLZGLAFFOMWPB-UHFFFAOYSA-N 0.000 claims 1
- HVHNMNGARPCGGD-UHFFFAOYSA-N 2-nitro-p-phenylenediamine Chemical compound NC1=CC=C(N)C([N+]([O-])=O)=C1 HVHNMNGARPCGGD-UHFFFAOYSA-N 0.000 claims 1
- UXKLYBMQAHYULT-UHFFFAOYSA-N 4-(2-hydroxyethylamino)-3-nitrophenol Chemical compound OCCNC1=CC=C(O)C=C1[N+]([O-])=O UXKLYBMQAHYULT-UHFFFAOYSA-N 0.000 claims 1
- BXIXXXYDDJVHDL-UHFFFAOYSA-N 4-Chloro-ortho-phenylenediamine Chemical compound NC1=CC=C(Cl)C=C1N BXIXXXYDDJVHDL-UHFFFAOYSA-N 0.000 claims 1
- IQXUIDYRTHQTET-UHFFFAOYSA-N 4-amino-3-nitrophenol Chemical compound NC1=CC=C(O)C=C1[N+]([O-])=O IQXUIDYRTHQTET-UHFFFAOYSA-N 0.000 claims 1
- RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 claims 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 claims 1
- KKJZEUXMWDXPAU-GJHDBBOXSA-N Bandrowski's base Chemical compound NC\1=C\C(=N/C=2C=CC(N)=CC=2)\C(N)=C/C/1=N\C1=CC=C(N)C=C1 KKJZEUXMWDXPAU-GJHDBBOXSA-N 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 239000004264 Petrolatum Substances 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- HUFIRBOBXZUFPV-UHFFFAOYSA-N benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1.OC1=CC=CC(O)=C1 HUFIRBOBXZUFPV-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 229940117173 croton oil Drugs 0.000 claims 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960002311 dithranol Drugs 0.000 claims 1
- 210000000883 ear external Anatomy 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 230000002884 effect on inflammation Effects 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 125000005067 haloformyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 210000004247 hand Anatomy 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- 230000000622 irritating effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims 1
- 125000002418 nitrosooxy group Chemical group [O-][N+](=O)O* 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000036281 parasite infection Effects 0.000 claims 1
- 235000015927 pasta Nutrition 0.000 claims 1
- 229940066842 petrolatum Drugs 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- XBRWELTXMQSEIN-UHFFFAOYSA-N squaric acid dibutyl ester Chemical compound CCCCOC1=C(OCCCC)C(=O)C1=O XBRWELTXMQSEIN-UHFFFAOYSA-N 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229960004560 triaziquone Drugs 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (25)
1. Method of preventing or treating inflammatory disorders by administration of compounds which can induce a contact dermatitis. This method can be used in the prophylaxis or therapy of prediabetes or diabetes.
2. Method of preventing or treating inflammatory disorders by administration of compounds which can induce a contact dermatitis. This method can be used in the prophylaxis or therapy of celiac disease, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, multiple sclerosis, hyperthyroidism, hypothyroidism, Hashimoto's thyroiditis, arteriosclerosis, myocardie infarction, psoriasis, parapsoriasis, pemphigus, lupus and/or associated complications in an individual.
3. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) by administration of compounds which induce an immune mediated dermatitis. Molecules according to claim 1 which can induce an immune mediated contact dermatitis, and can be used for the treatment or prevention of inflammatory disorders are characterized by the molecular formulas: C6-H8-N2 and C6-H3-C1-N2-04. Respectively 1,4-phenylenediamine (PPD) and 2,4-dinitro-1-chlorobenzene (DNCB), and derivates of PPD such as Bandrowski's base, 1,4-benzoquinone, 4-nitro-o-phenylenediamine, 2-chloro-p-phenylenediamine, 4-chloro-o-phenylenediamine, and 2-nitro-p-phenylenediamine.
4. Compounds according to claim 1-2 with the ability to induce an immune mediated dermatitis, which may have the same effect on inflammation: 2,4-dinitro-l-fluorobenzene (DNFB), 2,4,6-trinitrochlorohenzene (TNCB), 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone), 5-chloro-2-methyl-4-isothiazolin-3-one, 4-amino-3-nitrophenol, 3-nitro-p-hydroxyethylamino-phenol (4-i(2-Hydroxyethyl)amino)-3-nitrophcnol). resorcinol (1,3-Benzenediol), toluene-2,5-diamine (2,5-Diaminotoluene), and toluene-2,5-diaminesulfate (2,5-Diaminotoluene sulphate).
5. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of compounds which can induce dermatitis and which have previously been used in the treatment of alopecia areata: 2,3-Diphenylcyclopropenone (DPCP), 3,4-Dibutoxy-3-cyclobutene-l,2-dione (squaric acid dibutyl ester), and triethyleneiminobenzoquinone (trenimon or triaziquone).
6. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of compounds which can induce irritative dermatitis. These compounds are non-specific irritants which can cause an irritant contact dermatitis: Dithranoi (anthralin) and croton oil.
7. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of compounds which act as inducers of dermatitis (as mentioned in claim no 2-5) and their derivate compounds with the following types of side chains: Hydroxyl (R-OH), Aldehyde (R-CHO), Carboxyl (R-COOH), Amine (R-NH2), Azide (R-N3), Cyanate (R-OCN), Isocyanide (R-NC), Isocyanate R-NCO, Isothiocyanate (R-NCS), Nitrile (R-CN), Nitrosooxy (R-ONO), Nitro (R-N02), Nitroso (R-NO), Pyridyl (R-C5H4N), Sulfo (R-SO3H), Sulfhydryl (R-SH), Thiocyanate (R-SCN), Benzyl (R-CFTC^Hs), Phenyl (R- C6H5), Haloformyl (R-COX), Methyl (R-CH3), Ethyl (R-CH2CH3), Propyl (R-CH2CH2CH3), Isopropyl (R-CH(CH3)2), Butyl (R-CH2CH2CH2CH3), Isobutyl (R-C(CH3)3) and Halo (R-X)
8. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of all compounds which induce dermatitis. .
9. Compounds according to claims 1-8 characterized that the use is for the prophylaxis or therapy of inflammatory disorders by inducing a clinical or subclinical dermatitis in a certain but unspecific area of the body in order to induce a condition which by immune or other mechanisms oppose the development of the mentioned diseases.
10. The typical places of topical application of the reagents mentioned in claims 1-8, are: The antebrachium (lower-arm), the upper-arm, the wrist, the hands, the chest, the back, the neck, behind the ears, the femura region, the lower legs, or the feet.
11. All other places on the body, including the mouth or other body cavities are to be considered areas for application for the reagents mentioned in claim 1-8.
12. The reagent causing clinical or subclinical dermatitis (or the allergen), mentioned in claims 1-8, can also be administrated; perorally, intranasally, intrarectally, intravaginally, intradermally, subcutantneously, the outer ear or ear tract, or conjunctiva.
13. The reagent causing dermatitis (or the allergen) mentioned in claim 1-8 is to be applicated in an area from less than a droplet or injection area to an extented part of the body covering up to the total body area. A typical topical treatment area would be 1-9 cm2.
14. The reagent (or allergen) mentioned in claims 1-8, is to be applicated in water or in any buffer solution based on water, alcohols, aldehydes/ketones, fatty acids, or other fats implemented in pasta or cream.
15. The reagent (or allergen) mentioned in claims 1-8, is applicated directly as a fluid, as an ointment or using a spray, as a wash of product such as a soap, or can be emulsified or dissolved in a cream (e.g. petrolatum) and applicated in a chamber taped to the area. The reagent (or allergen) can also be emulsified or bound to a plaster, wristband, bracelet, sock, anklet, ring or other material which can be worn.
16. The reagent (or allergen) mentioned in claims 1-8, can be applicated in a tablet form or given as an injection or other deposit form.
17. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having inflammatory diseases, such as prediabetes or diabetes.
18. Prediabetes or diabetes, to be prevented or treated according to claim 17 are: Type 1 diabetes, Type 2 diabetes, MOODY, LADA, gestational diabetes, diabetes with characteristics of both type 1 and type 2 diabetes, and other forms of diabetes; furthermore prevention or treatment of diabetic complications or risk hereof, such as nurophatic nephropaty, retinophaty, or orther micro- or macrovascular disorders.
19. The individuals to be treated in accordance with claim 1-8 are persons having the risk of background population to develop diabetes; or any increased risk due to certain tissue types or other genetic markers, due to relatives with diabetes, due to presence of antibodies such as ICA anti-GAD, anti-IA2, anti-insulin, anti-C-transporter-protein, and/or cellular reactions against insulin-producing beta-cells or their components, due to laboratory or clinical tests indicating impaired glycaemic conditions.
20. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having inflammatory diseases, such as celiac disease, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, multiple sclerosis, hyperthyroidism, hypothyroidism, Hashimoto's thyroiditis, arteriosclerosis, myocardic infarction, psoriasis, parapsoriasis, pemphigus, lupus and/or associated complications in an individual.
21. The individuals to be treated, are patients with inflammatory diseases (claim 20) which are in a preface, have the disease or have complications due to the disease
22. The individuals to be treated are persons having the risk of background population to develop an inflammatory disorder mentioned in claim 20, or any increased risk to develop any of these diseases due to certain tissue types, antibodies or other genetic markers, due to relatives with disease, due to presence of antibodies and/or cellular reactions.
23. Other diseases to consider for treatment are, atopic dermatitis, parasite infections, infections and other skin diseases.
24. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having cancer in the oesophagus, urine bladder, cervix uteri, pharynx, skin cancer, colon and/or rectum.
25. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having all other forms of cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801600A DK200801600A (en) | 2008-11-17 | 2008-11-17 | Method for treatment of inflammatory diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801600A DK200801600A (en) | 2008-11-17 | 2008-11-17 | Method for treatment of inflammatory diseases |
| DK200801600 | 2008-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200801600A true DK200801600A (en) | 2010-05-18 |
Family
ID=42227570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA200801600A DK200801600A (en) | 2008-11-17 | 2008-11-17 | Method for treatment of inflammatory diseases |
Country Status (1)
| Country | Link |
|---|---|
| DK (1) | DK200801600A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051458A1 (en) * | 2013-10-08 | 2015-04-16 | Lu qing-bin | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
-
2008
- 2008-11-17 DK DKPA200801600A patent/DK200801600A/en not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051458A1 (en) * | 2013-10-08 | 2015-04-16 | Lu qing-bin | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
| CN106232581A (en) * | 2013-10-08 | 2016-12-14 | 卢庆彬 | Non-platinum-based anticancer compounds for targeted chemotherapy |
| US10463662B2 (en) | 2013-10-08 | 2019-11-05 | Qing-Bin Lu | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
| CN114380700A (en) * | 2013-10-08 | 2022-04-22 | 卢庆彬 | Non-platinum based anti-cancer compounds for targeted chemotherapy |
| US11446294B2 (en) | 2013-10-08 | 2022-09-20 | Qing-Bin Lu | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vala et al. | Medicinal benefits of coconut oil | |
| Xu et al. | Posttraumatic administration of luteolin protects mice from traumatic brain injury: implication of autophagy and inflammation | |
| Provost et al. | Ethylenediamine contact dermatitis | |
| JP2022547922A (en) | Treatment of SYNGAP1 encephalopathy | |
| Li et al. | EPA and DHA inhibit endocytosis of claudin-4 and protect against deoxynivalenol-induced intestinal barrier dysfunction through PPARγ dependent and independent pathways in jejunal IPEC-J2 cells | |
| Gong et al. | Acid-sensing ion channel 3 decreases phosphorylation of extracellular signal-regulated kinases and induces synoviocyte cell death by increasing intracellular calcium | |
| Meneghini et al. | Contact allergy to antirheumatic drugs. | |
| DK200801600A (en) | Method for treatment of inflammatory diseases | |
| EP3766503A4 (en) | APPLICATION OF A MICRO-RNA-210 INHIBITOR IN THE PREPARATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES | |
| CN103736030B (en) | Treat compound Chinese medicinal preparation of dysmenorrhoea and its production and use | |
| Shaffique et al. | Anti-hyperuricemic potential of Rhododendron tomentosum Harmaja syn. Ledum palustre L. 30c and 1M in potassium oxonate induced rat model | |
| Fisher | Necrolytic acral erythema: a review of the literature | |
| Berih et al. | Allergic dermatitis: black henna (para-phenylenediamine) use among the east African patient population in a general practice setting | |
| KR20190075004A (en) | Food or pharmaceutical composition for reducing visceral obesity with decursin or decursinol angelate | |
| KR20190008235A (en) | Carboxylic acids for treating / preventing skin diseases | |
| Maibach et al. | Vulvar dermatitis and fissures--irritant dermatitis from methyl benzethonium chloride. | |
| Dhar et al. | Eczema and Dermatitis | |
| Gunarathna et al. | Effect of Panchatikta Ghrita and Gandhakadi Taila in the Management of Kitibha (Psoriasis)-A Case study | |
| Han et al. | Acute bullous irritant contact dermatitis caused by a Pulsatilla koreana extract | |
| Bhadoriya | Homeopathic approaches for the management of psoriasis: a review | |
| Van Onselen | Treating dry skin conditions in children and babies | |
| Pereira et al. | A Systematic Patent Review (2008-2023) for Treatment in Pregnancy | |
| Silviya et al. | Body circumferences and muscle-fat ratios of young people from Smolyan region | |
| Furau et al. | Effect of a guaiazulene-containing ointment on nipple and areola area health of women | |
| AU2017266729A1 (en) | Carboxylic acids for early childhood application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |